RxDoctor Payments Data

Hector Colon Rivera, MD

Addiction Psychiatry · Philadelphia, PANPI 1508132119

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,250 of the $22,583 with a category attached, or 85.2%. AbbVie accounts for 90.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $20,114, more than ten times the $280 reported in 2019.

$22,583in general payments, 2019–2025

Across 141 payments — averaging $160.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$653
  • Johnson & Johnson$378
  • Otsuka America Pharmaceutical, Inc.$376
  • Sunovion Pharmaceuticals Inc.$137
  • Paratek Pharmaceuticals, Inc.$124
  • plus $507 from 7 others

What the payments were for

  • Speaking & faculty fees$19,25085%
  • Travel & lodging$1110%
  • Food & beverage$3,17514%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few addiction psychiatry providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$9,972
Medicare patients
52
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole22$2,173
Alprazolam252$922
Mirtazapine78$786
Doxepin Hcl40$709
Hydroxyzine Hcl87$526
Clonazepam57$520
Sertraline Hcl77$473
Bupropion XlBupropion Hcl31$462
Fluoxetine Hcl54$458
Quetiapine Fumarate44$318
Zolpidem Tartrate71$315
Risperidone20$292
Trazodone Hcl65$288
Buspirone Hcl32$260
Venlafaxine Hcl ErVenlafaxine Hcl27$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$72$47377 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other addiction psychiatry in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →